Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.
Target Price
The average target price of NMRA is 9.7 and suggests 377% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell